Alberico L. Catapano
Surgery · 2010–2022
A researcher in the Science corpus: 23 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Surgery — 432 citations into it
- Endocrinology, Diabetes and Metabolism — 289 citations into it
- Epidemiology — 100 citations into it
- Immunology — 72 citations into it
- Molecular Biology — 58 citations into it
Whom Alberico L. Catapano trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Alberico L. Catapano overall
Papers from Alberico L. Catapano's perspective
Ordered by how strongly the researchers Alberico L. Catapano trusts endorse each paper. Same corpus, a different order for every researcher.
- Rosuvastatin in older patients with systolic heart failure. (Current Atherosclerosis Reports)
- Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. (Journal of the American College of Cardiology)
- Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. (Arteriosclerosis, Thrombosis and Vascular Biology)
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemia (Nature Genetics)
- Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques: Implications for Plaque Stabilization (Circulation)
- Interpretation of the evidence for the efficacy and safety of statin therapy. (The Lancet)
- Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. (Journal of the American Medical Association (JAMA))
- C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. (New England Journal of Medicine)
- Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. (Journal of the American Medical Association (JAMA))
- Genetic Risk, Coronary Heart Disease Events, and the Clinical Benefit of Statin Therapy (The Lancet)
Their papers
- Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement (2022) — 1,097 citations
- Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 (2021) — 4,796 citations
- Global epidemiology of dyslipidaemias (2021) — 707 citations
- Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) — 742 citations
- Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel (2020) — 1,302 citations
- Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 (2020) — 9,012 citations
- EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. (2020) — 692 citations
- 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019) — 4,665 citations
- Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol (2019) — 630 citations
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. (2019) — 3,945 citations
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel (2017) — 3,303 citations
- Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. (2016) — 670 citations
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice. (2016) — 4,245 citations
- Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management (2015) — 1,260 citations
- Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment (2015) — 768 citations
- Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (2014) — 765 citations
- Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease (2013) — 2,141 citations
- LOX-1, OxLDL, and Atherosclerosis (2013) — 738 citations
- ESC/EAS Guidelines for the Management of Dyslipidaemias (2013) — 2,678 citations
- Identification of seven loci affecting mean telomere length and their association with disease (2013) — 909 citations